MannKind Q3 Earnings Call Highlights

Impact · against what's priced in

MannKind (MNKD) provides positive catalysts via an accelerated path to profitability driven by a rapid shift to the higher-margin ReadyFlow version of FUROSCIX and strong pediatric Afrezza adoption. United Therapeutics (UTHR) sees modest benefit from continued royalty growth and the aforementioned ralinepag milestone potential.

MNKD+0.40

No priced-in read yet

In context

The company expects a return to profitability in Q4 2026 and full-year profitability by 2027, supported by a 70% sequential increase in FUROSCIX revenue to $38 million and the shift to lower-cost ReadyFlow shipments.

Read from the article alone

• revenue growth▲9%
• healthcare▲2%
• pharmaceuticals
• earnings
• biotech
• MNKD
• UTHR
• clinical trials